Compound shows anticonvulsant activity at 30 mg/kg in the initial tests with no signs of ataxia until 300 mg/kg. The activity seen with 30 mg/kg 37 is still present 4 h postdose. Compound is effective against seizures induced by maximal electroshock but does not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that Compound would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound is selected for clinical trials.